This product will give you access to the webinar only. If you would like continuing education credit for the webinar, see the table below to purchase the webinar + CME/CMLE or webinar + SAM.


In this webinar, Dr. Karen Weck will present the recommendations of The AMP Pharmacogenomics Working Group of the Clinical Practice Committee for inclusion of variants in CYP2C19 genotyping panels. The working group has published consensus, evidence-based recommendations using criteria such as allele function, population frequency, and availability of reference materials. The recommendations include a Tier 1 minimum set of alleles and defining variants that should be included in all clinical CYP2C19 PGx tests, and a Tier 2 list of additional optional alleles that do not currently meet all of the criteria for inclusion in Tier 1. These recommendations are intended to aid clinical laboratory professionals when designing and validating CYP2C19 genotyping assays, promote standardization of testing across different laboratories, and complement existing clinical guidelines for pharmacogenetic testing.

Practice Guideline Available Here

Speaker: Karen E. Weck, MD

Host: Joshua Deignan, PhD

Duration: 1 hr

Level of Instruction: Basic


Click on the links below to purchase continuing education credit.

Credit Type Number of Credit Hours Click on link to purchase:

Purchase Webinar + CME/CMLE

(Free for AMP members)

SAM 1.0

Purchase Webinar + SAM

(Free for AMP members)

Continuing Education Credit must be purchased and claimed by March 21, 2021


* You may not submit SAMs and CME/CMLE credit for the same content.

You may also be interested in:


Note: Members of AMP can access this webinar at no cost. Join the AMP Family!

All sales are final. No refunds will be issued.

No digital files may be reproduced or transmitted in any form, by any means, electronic or mechanical. By purchasing a product, you agree to not share any of the course materials, including videos, downloadable slide presentations, outlines, manuscripts, etc. without explicit and written permission from AMP.


Course Information
Course Date:
March 21, 2018
Course Objectives
  • Describe the key characteristics of pharmacogenetic alleles that are recommended for inclusion in clinical testing platforms by the AMP PGx working group.
  • Give examples of key drugs in clinical use that are affected by CYP2C19 genetic variability affecting enzymatic activity.
  • List the three most common alleles associated with CYP2C19 altered metabolism and their respective effects on enzymatic function.
Recommendations for Clinical CYP2C19 Genotyping Allele Selection
Speaker Information
Karen E. Weck MD   [ view bio ]
Individual topic purchase: Selected
Weck Presentation
AMP Regular Member: $0.00
AMP Technologist Member: $0.00
AMP Associate Member: $0.00
Non-member Price: $195.00